U.S. License Holder:
Genentech
Date of License:
November-16-2017
Last Update:
Sep-30-2024
FDA-Approved Indications
HEMLIBRA (emicizumab) is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients age newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.